hotspot -WSS

hotspot

author：comprehensive 2025-10-01 00:16:39 - browse：6737

This image provided by Novo Nordisk in January 2023, shows packaging for the company's Wegovy drug. — Novo Nordisk via AP

PHILADELPHIA — Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in a landmark cardiovascular trial that affirms the treatment offers health benefits beyond weight loss.

The company in August had announced that in this trial, called Select, Wegovy reduced the overall rate of major heart problems — heart attacks, stroke, or cardiovascular-related death — by 20%. That finding, which was the primary outcome the trial set out to study, was stronger than many were expecting and led Novo’s stock to surge.

But details of the study, including risk reductions for each specific heart complication, were not released until Saturday, when they were presented here — before a standing-room only crowd — as the first major session of the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： What should King Charles tell the public about his cancer?

WSS

Readout LOUD podcast: How biotech is using artificial intelligence

2024 GOP presidential candidates spar over abortion in debate

Senators start work on Medicare physician payment reform

Neuroscience startup Neumora files for IPO

Doctors' information doesn't help them choose wisely when sick

AstraZeneca bets AAV gene therapy will still deliver the goods

knowledge

hotspot

leisure time

Dobbs anniversary: the lost opportunity of abortion as health care

Readout LOUD podcast: How biotech is using artificial intelligence

Trump demands the U.S. pay no more for drugs than other countries … again

In science, is the line between industry and academia shifting?

Duchenne breakthrough therapy leaves behind pioneering families

AstraZeneca challenges Medicare drug negotiation program

Medical leaders decry Supreme Court decision on affirmative action

As pharma fights Medicare drug negotiation, hospitals, docs silent

Tori Bowie and the unacceptable rates of Black maternal death

The dental labor crisis is a moment of opportunity

Wikipedia

The dental labor crisis is a moment of opportunity

The Readout: Gilead, Bernie Sanders, and other pharma news

How to make AI work for medicine

Medicare Advantage proposed rates disappoint insurers

Key House Republican on health care plans exit from Congress

As pharma fights Medicare drug negotiation, hospitals, docs silent

hotspot

hotspot

focus

focus